XTX Topco Ltd Lowers Stake in argenx SE (NASDAQ:ARGX)

XTX Topco Ltd decreased its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 59.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,040 shares of the company's stock after selling 2,990 shares during the quarter. XTX Topco Ltd's holdings in argenx were worth $1,255,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in argenx by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares in the last quarter. Clearbridge Investments LLC raised its stake in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after acquiring an additional 40,330 shares in the last quarter. Jennison Associates LLC lifted its position in argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after acquiring an additional 64,183 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in argenx in the third quarter valued at $88,339,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after purchasing an additional 143,834 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Up 1.5 %

Shares of NASDAQ:ARGX traded up $8.61 during trading on Friday, reaching $596.20. The stock had a trading volume of 321,813 shares, compared to its average volume of 308,970. The stock has a market cap of $36.23 billion, a P/E ratio of -677.50 and a beta of 0.60. The business has a fifty day moving average price of $602.53 and a 200-day moving average price of $606.37. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts forecast that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ARGX shares. Citigroup upped their target price on argenx from $681.00 to $796.00 and gave the company a "buy" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $715.00 price target on shares of argenx in a research report on Friday, April 11th. Robert W. Baird increased their price objective on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 4th. Finally, William Blair restated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $699.28.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.